Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v17.i2.20
62 pages

Poly(ethylene glycol) Conjugated Drugs and Prodrugs: A Comprehensive Review

Richard B. Greenwald
Enzon, Inc., 20 Kingsbridge Road, Piscataway, New Jersey, 08854
Charles D. Conover
Enzon, Inc., 20 Kingsbridge Road, Piscataway, New Jersey, 08854
Yun H. Choe
Enzon, Inc., 20 Kingsbridge Road, Piscataway, New Jersey, 08854

ABSTRAKT

Low molecular weight Polyethylene glycol) (PEG) (< 20,000)-drug conjugates, prepared over a 20-year period, have been scrutinized and their properties and efficacy reviewed. No commercial products have thus far been reported for these types of compounds. However, during the past 5 years a renaissance in the field of PEG-(anticancer) drug conjugates has taken place, initiated by the use of higher molecular weight PEGs (> 20,000), especially 40,000, which is estimated to have a plasma circulating half-life of approximately 8-9 h. This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models and has led to a clinical candidate. Recent applications of high molecular weight PEG prodrug strategies to amino-containing drugs are also detailed.


Articles with similar content:

Pulmonary Drug Delivery Systems: Recent Developments and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Th. F. Vandamme, N. Butz, H. M. Courrier
Nano-Aggregates: Emerging Delivery Tools for Tumor Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 6
Vinod Kumar Sharma, Ankit Jain, Vandana Soni
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Sathish Dyawanapelly, Animesh Kumar, Manish K. Chourasia
Exploiting the Tumor Phenotype Using Biodegradable Submicron Carriers of Chemotherapeutic Drugs
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Aliasger K. Salem, Sean M. Geary
Biodegradable Microspheres for Parenteral Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.22, 2005, issue 6
Vivek Ranjan Sinha, A. Trehan